Clinical trial costs are rising, too many cancer research applications are going unfunded, and the White House proposed no new money for the National Cancer Institute despite its plan to cut the disease’s death rate in half.
Yet Ned Sharpless remains optimistic about the prospects for the institute he’s led for nearly five years and its role in President Joe Biden’s Cancer Moonshot 2.0.
“There will be significant investment in the NCI as part of the president’s priorities in the future,” Sharpless said in an interview. “Any mission to end cancer as we know it is going to involve the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.